PTD-DBM
Peptide Transduction Domain-Dishevelled Binding Motif
Popular for:Hair growth, androgenetic alopecia, Wnt pathway activation, topical hair peptide
0
Registered Trials
0
Trial Publications
4
PubMed References
Preclinical
Evidence Level
Overview
PTD-DBM is a cell-penetrating peptide developed by researchers at Yonsei University in South Korea. The short version: people usually care about it for hair growth, androgenetic alopecia, wnt pathway activation, topical hair peptide, but the strength of the evidence depends heavily on indication and study type.
PTD-DBM is a cell-penetrating peptide developed by researchers at Yonsei University in South Korea. It promotes hair growth by targeting the Wnt/beta-catenin signaling pathway — specifically by inhibiting CXXC5, a negative regulator that normally suppresses hair follicle neogenesis.
The 2017 study published in the Journal of Investigative Dermatology demonstrated that PTD-DBM could stimulate new hair follicle formation (not just maintenance of existing follicles) in mouse models, which is exceptionally rare for any hair loss treatment. Most hair loss treatments slow loss or maintain existing hair — PTD-DBM showed actual new follicle generation.
Research Snapshot
What the evidence says
PreclinicalPTD-DBM currently shows 0 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 4 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 0 registered trials are tracked from ClinicalTrials.gov intervention records.
- 0 PubMed clinical-trial publications are indexed.
- 0 PubMed randomized controlled trial publications are indexed.
- 4 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
PTD-DBM disrupts the interaction between CXXC5 protein and Dishevelled (Dvl), a key mediator in the Wnt signaling cascade.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
0
Registered Trials
0
Trial Publications
0
RCT Publications
4
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
0
Registered trials
0
Trial publications
0
RCT publications
4
PubMed references
1
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
PTD-DBM
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View sourceNot FDA-approved. Pre-clinical research compound. Key study: Lee et al., Journal of Investigative Dermatology, 2017. No large-scale human trials. Available from some research peptide vendors for topical use.
Key PubMed References
Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies.
Mehta A, Motavaf M, Raza D, et al. · Cells · 2025
PMID: 40497955CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD.
Ryu YC, Park J, Kim YR, et al. · Cells · 2023
PMID: 36831222Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.
Lee SH, An S, Ryu YC, et al. · Advanced healthcare materials · 2023
PMID: 36854308The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.
Lee SH, Kim MY, Kim HY, et al. · The Journal of experimental medicine · 2015
PMID: 26056233Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for PTD-DBM yet.
Side Effects & Safety
- Very limited human safety data - Scalp irritation at application site possible - Long-term effects unknown - Efficacy in humans not yet established at scale
Known Interactions
No curated interaction entry is live for PTD-DBM yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.